跳至主要内容
临床试验/NCT01259141
NCT01259141已完成不适用

The Optimization of Mycoplasm Pneumonia Antibiotic Therapy: Multi-centre, Prospective, Randomized Controlled Study

Capital Medical University1 个研究点 分布在 1 个国家目标入组 208 人开始时间: 2010年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
208
试验地点
1
主要终点
Time to resolution of fever (defined as the period from start of study-drug to relief of fever)

研究概览

简要总结

Mycoplasma pneumoniae, an important pathogen of community acquired pneumonia,are becoming more and more resistant to macrolide. The study aim is to optimize anti-infection therapy.

详细描述

Mycoplasma pneumoniae was one of important atypical pathogens of community acquired pneumonia. As lack of cell wall, β-lactam medicines were invalid, however, macrolides, tetracyclines and quinolones were effective. But from 2001, many countries reported macrolide- resistant Mycoplasma pneumoniae. Typically, erythromycin was first-line antibiotic medicine. With the resistance increasing, Mycoplasm pneumonia treatment will become more and more difficult. Thus, optimization of Mycoplasm pneumonia antibiotic therapy is very important.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Confirmed community acquired pneumonia
  • 60ys≥age≥18 ys
  • Respiratory symptom (cough accompanied by little or no sputum)
  • New infiltration showed by chest radiology(x-ray or CT)
  • Lung signs was not obvious
  • White blood cell<10,000/mm3
  • Without underlying diseases or mild

排除标准

  • Age<18ys or >60ys
  • Pregnancy or breast-feeding
  • Over one week after the onset of symptoms
  • HIV infection
  • Recent 90-day hospitalized history(length of stay greater than 2 days)
  • Live in nursing homes or rehabilitation hospitals
  • Taken macrolides or quinolones medicines before enrollment

研究组 & 干预措施

Cephalosporins and azithromycin

Experimental

干预措施: Cephalosporins and azithromycin (Drug)

Moxifloxacin

Experimental

干预措施: Moxifloxacin (Drug)

结局指标

主要结局

Time to resolution of fever (defined as the period from start of study-drug to relief of fever)

时间窗: one month

usually duration of fever is about one to two weeks

Time to resolution of fever (defined as the period from onset to relief of fever)

时间窗: one month

usually duration of fever is about one to two weeks

次要结局

  • Duration of antibiotics(one year)
  • Time to resolution of respiratory symptoms(defined as the period from start of study-drug to relief of symptoms)(one year)
  • Time to resolution of respiratory symptoms(defined as the period from onset to relief of symptoms)(one year)
  • Proportion of antibiotics change(one year)
  • Proportion of resolution of fever after antibiotics therapy for 24 hours(one year)
  • Proportion of resolution of fever after antibiotics therapy for 72 hours(one year)
  • Antibiotic-related adverse reaction(one year)

研究者

发起方
Capital Medical University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Bin Cao

Professor

Capital Medical University

研究点 (1)

Loading locations...

相似试验